- Aurigene Pharmaceutical Services has signed a long-term Manufacturing and Supply Agreement for commercial drug-product manufacturing and supply across the US, Europe, Canada and emerging markets.
- The initial portfolio includes 20+ products, with expected annual volumes of approximately 18 million units at full commercialization and revenues expected to begin in 2028.
Aurigene Pharmaceutical Services has entered into a strategic, long-term Manufacturing and Supply Agreement with a global pharmaceutical company for the commercial manufacturing and supply of a diversified drug-product portfolio. The agreement covers the US, Europe, Canada and emerging markets, with manufacturing to take place at Aurigene facilities in India.
The agreement establishes a full-service framework covering technology transfer, process development, scale-up, validation, commercial manufacturing and long-term supply. The initial portfolio includes more than 20 products across sterile injectables, biologics and topicals.
The partnership is expected to progress through a phased technology transfer program over the next two to three years. At full commercialization, the portfolio is expected to represent approximately 18 million units annually, with most of the volume comprising injectables. Revenues are expected to commence in calendar year 2028.
The agreement expands Aurigene’s drug-product CDMO and CMO capabilities, particularly in sterile injectables and biologics, while complementing its existing development and manufacturing expertise across the pharmaceutical value chain. The company said the collaboration will provide long-term revenue visibility and support the scale-up of its drug-product business.
“We are delighted to enter into this strategic, long-term collaboration. This partnership reflects the confidence global innovators place in our integrated drug-product development and manufacturing capabilities of sterile injectables, biologics and topicals, our proven quality and regulatory track record, and our ability to support complex technology transfers and commercial supply. It provides long-term revenue visibility, accelerates the scale-up of our drug-product business, and reinforces our commitment to reliable, high-quality supply to patients worldwide.”
Akhil Ravi, ChiefExecutive Officer, Aurigene Pharmaceutical Services
